These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25693997)

  • 21. Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison.
    Bloemers J; van Rooij K; de Leede L; Frijlink HW; Koppeschaar HP; Olivier B; Tuiten A
    Br J Clin Pharmacol; 2016 Jun; 81(6):1091-102. PubMed ID: 26804967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of a Novel Sildenafil Orodispersible Film Administered by the Supralingual and the Sublingual Route to Healthy Men.
    Loprete L; Leuratti C; Frangione V; Radicioni M
    Clin Drug Investig; 2018 Aug; 38(8):765-772. PubMed ID: 29909432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of rilpivirine and boceprevir coadministration in HIV-infected patients treated for acute hepatitis C virus infection.
    Hullegie SJ; de Winter BC; Posthouwer D; Koopmans PP; Claassen MA; Burger DM; Rijnders BJ
    AIDS; 2016 Jan; 30(3):529-30. PubMed ID: 26558734
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study.
    Solans A; Izquierdo I; Donado E; Antonijoan R; Peña J; Nadal T; Carbó ML; Merlos M; Barbanoj M
    Clin Ther; 2008 Sep; 30(9):1639-50. PubMed ID: 18840369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
    Seden K; Back D
    Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.
    Jackson A; D'Avolio A; Watson V; Bonora S; Back D; Taylor J; Armenis K; Gazzard B; Moyle G; Boffito M
    J Antimicrob Chemother; 2011 Apr; 66(4):885-9. PubMed ID: 21393207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy.
    Boglione L; De Nicolò A; Cardellino CS; Ruggiero T; Ghisetti V; Cariti G; Di Perri G; D'Avolio A
    Clin Microbiol Infect; 2015 Feb; 21(2):205.e1-3. PubMed ID: 25658567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio
    Ring A; Morris T; Wozniak M; Sullo N; Dott W; Verheyden V; Kumar T; Brunskill N; Vaja R; Murphy GJ
    Br J Clin Pharmacol; 2017 Apr; 83(4):709-720. PubMed ID: 27779776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
    Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of fasting bioavailability among 100-mg commercial, 100-mg generic, and 50-mg chewable generic sildenafil tablets in healthy male Mexican volunteers: a single-dose, 3-period, crossover study.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; García-González A; Ramírez-San Juan E
    Clin Ther; 2012 Mar; 34(3):689-98. PubMed ID: 22386826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
    Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
    Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Boceprevir.
    Prescrire Int; 2012 Apr; 21(126):89-92. PubMed ID: 22515132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
    Devineni D; Vaccaro N; Polidori D; Rusch S; Wajs E
    Clin Ther; 2014 May; 36(5):698-710. PubMed ID: 24726680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.
    Macha S; Sennewald R; Rose P; Schoene K; Pinnetti S; Woerle HJ; Broedl UC
    Clin Ther; 2013 Mar; 35(3):226-35. PubMed ID: 23497760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.
    Trembling PM; Tanwar S; Dusheiko GM
    Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
    Reesink HW; Fanning GC; Farha KA; Weegink C; Van Vliet A; Van 't Klooster G; Lenz O; Aharchi F; Mariën K; Van Remoortere P; de Kock H; Broeckaert F; Meyvisch P; Van Beirendonck E; Simmen K; Verloes R
    Gastroenterology; 2010 Mar; 138(3):913-21. PubMed ID: 19852962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of drug interactions of saxagliptin with sildenafil in healthy volunteers.
    Mansour RY; ElBorolossy R; Shaheen SM; Sabri NA
    Eur J Clin Pharmacol; 2022 Dec; 78(12):1935-1944. PubMed ID: 36214883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.
    Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP
    Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.